 
 This is a case-based discussion on how DynamX Bioadaptor improves patients' clinical outcomes in real life. Also the faculty will delve into the current unmet long-term needs in PCI with DES.
They will also discuss the 2 year findings of the Bioadaptor RCT trial and 1 year findings of INFINITY SWEDEHEART trial and provide their perspective on the clinical implications of these findings and potential impact on the future of PCI in light of the outcomes.
1-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after 6 months.
Learn more about INFINITY-SWEDEHEART outcomes
	Chairwoman
	Rasha Al-Lamee, London, United Kingdom
	Speakers
	Johan Bennett, Leuven, Belgium 
	Davide Capodanno, Catania, Italy
	David Erlinge, Lund, Sweden
	Teguh Santoso, Jakarta, Indonesia
| 
					Welcome, Clinical Rationale for Bioadaptive PCI 
						Rasha Al-Lamee | 
| 
						Overview of Latest Clinical Evidence: 
 | 
| Discussion: Clinical implications and lessons learned from multiple RCTs Davide Capodanno | 
| Case Presentations: Bioadaptor in practice Teguh Santoso | 
| Closing Remarks and Take-aways Rasha Al-Lamee | 
Bimlendu K. good idea for preservation of vascular remodelling and endothelial function